Back to search
FDAFDA · Food and drugs·Recall number D-0141-2024

ceFAZolin sodium in Sterile Water for injection, Injectable Solution, 1g/10mL (0.1 g per mL), Syringe, Rx only, Wells Pharma, NDC 73702-131-10

Published December 13, 2023 · Recall initiated: November 22, 2023

Summary

FDA records drug Class II recall D-0141-2024, published December 13, 2023 and initiated November 22, 2023. Recalling firm: Wells Pharma of Houston LLC; Status: Completed; Reported quantity: 825 syringes; Lot: Lot # 11092313110#01, Exp 01/12/24. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Completed — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of assurance of sterility.

What to do

Voluntary: Firm initiated · Telephone

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Wells Pharma of Houston LLC
Distributor
Philadelphia, Pennsylvania.
Lot
Lot # 11092313110#01, Exp 01/12/24
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was ceFAZolin sodium in Sterile Water for injection, Injectable Solution, 1g/10mL (0.1 g per mL), Syringe, Rx only, Wells Pharma, NDC 73702-131-10 recalled?

Yes. FDA published recall D-0141-2024 on December 13, 2023. Reported hazard: Lack of assurance of sterility.

What should I do if I have this product?

Voluntary: Firm initiated · Telephone